The Trend of Antibiotic Consumption After the COVID-19 Pandemic: Approach to Future Outbreaks
DOI: https://doi.org/10.2147/idr.s460148
2024-06-04
Infection and Drug Resistance
Abstract:Salah H Elsafi, 1 Saleh H Almutairi, 2 Mujahid A Alsulaimani, 3 Salma AlBahrani, 4 Thekra N Al-Maqati, 1 Wafa K Alanazi, 2 Mohammed N Alanazi, 2 Abdullah A Alamri, 2 Majed Hamoud Alkhathami, 5 Rakkad A Alshammari, 5 Naif F Alharbi, 5 Yaser A Al Naam 1 1 Clinical Laboratory Sciences. Prince Sultan Military College of Health Sciences, Dhahran, Saudia Arabia; 2 Pharmacy Services Department, King Fahad Military Medical Complex, Dhahran, Saudi Arabia; 3 Basic Medical Unit, Prince Sultan Military College of Health Sciences, Dhahran, Saudia Arabia; 4 Infectious Disease Unit, Specialty Internal Medicine, King Fahhd Military Medical Complex, Dhahran Saudi Arabia; College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudia Arabia; 5 Department of Support Services, Prince Sultan Military College of Health Sciences, Dhahran, Saudia Arabia Correspondence: Yaser A Al Naam, Prince Sultan Military College of Health Sciences, P. O Box 33048, Dammam, 31448, Saudia Arabia, Email Background: Earlier reports suggested high rates of antibiotic utilization among COVID-19 patients despite the lack of direct evidence of their activity against viral pathogens. Different trends in antibiotic consumption during 2020 compared to 2019 have been reported. Purpose: The objective of this study is to assess the impact of COVID-19 pandemic on antibiotic consumption in the presence of active Antibiotic Stewardship Program. Methods: This study represented a five years assessment of the consumption of the commonly prescribed antibiotics measured as DDDs/100-Bed Days. We analyzed the data by using nonparametric Friedman and Friedman tests to compare the antibiotic consumption before and during the three subsequent waves of COVID-19. Results: Antibiotic consumption through the DDDs/100-BD has shown reduction in the median of antibiotics consumption of most antibiotics during the period of COVID-19 as compared to the pre-COVID-19 period, which was significant for meropenem and ciprofloxacin, except colomycin that slightly increased. Significant reduction in the consumption of imipenem and meropenem during the second and third waves as compared to the pre-COVID period. Throughout the years, significant reductions were observed between 2018 and 2019 (p=< .001), 2018 and 2020 (p=0.008), and 2018 and 2022 (p=0.002). Conclusion: The reduction in antibiotic consumption is attributed to the strong influence if the ASP and the reluctance of people to visit hospitals during the COVID-19 pandemic. Other related COVID-19 precautions such as physical distance, good hand hygiene, facemasks, that resulted in the prevention of secondary bacterial infections have contributed to the reduction in antibiotic utilization during the pandemic. Keywords: antimicrobial stewardship, ASP, COVID-19, defined daily doses, DDD, antibiotic consumption, Saudi Arabia Earlier reports suggested high rates of antibiotic utilization among COVID-19 patients despite the lack of direct evidence of their activity against viral pathogens. 1–3 A meta-analysis study showed a significant elevation of antibiotic prescribed for COVID-19 patients beyond the estimated prevalence of co-bacterial infections. 4 Bacterial co-infections among COVID-19 patients have been undoubtedly reported at low rates. 5 Therefore, the utilization of antibiotics in routine COVID-19 management has not been recommended. 6 However, patients with COVID-19 may develop secondary nosocomial infections with bacteria and fungi because of critical illness and prolonged hospitalizations. There is high concern that antimicrobials might be overused. This is because COVID-19 patients may receive both empiric and pathogen-directed broad-spectrum antimicrobials. Notwithstanding, it has been reported that more than half of the COVID-19 patients received antibiotics, while 72% of these did not have laboratory evidence of bacterial infection. 5 In fact, the prevalence of bacterial co-infection with COVID-19 was low. 7–11 Different trends in antibiotic consumption during 2020 compared to 2019 have been reported. 12 At the beginning of the pandemic, there was an increase in the prescribed antimicrobial due to early reports indicating that secondary bacterial infection resulted in great mortality. 13 It has been demonstrated that covid-19 pandemic associated with an increase in antimicrobial consumption. 14–16 Subsequently, a higher antimicrobial resistance rate among COVID-19 patients has been detected during the first 18 months of the pandemic. 17</s -Abstract Truncated-
pharmacology & pharmacy,infectious diseases